A comparative study of biomarkers for risk prediction in acute coronary syndrome-Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 636-643

  Kaski, Juan Carlos ^a   Fernández Bergés, Daniel J ^b   Consuegra Sánchez, Luciano ^c   Fernández, José M Cruz ^d   García Moll, Xavier ^e   Mostaza, José M ^f   Cebada, Rocío Toro ^g   Juanatey, José Ramón González ^h   Martínez, Gabriela Guzmán ^f   Marrugat, Jaume ⁱ  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL DON BENITO VILLANUEVA   (Spain)

^c Hospital Virgen del Rosell   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Acute coronary syndrome; Biomarkers; Inflammation; Myocardial infarction; Unstable angina

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CYSTATIN C; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; PADGEM PROTEIN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL STUDY; COMPARATIVE STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY RECANALIZATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ST SEGMENT DEPRESSION; SYSTEMIC INFLAMMATION EVALUATION IN NON ST ELEVATION ACUTE CORONARY SYNDROME STUDY; T WAVE INVERSION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROPORTIONAL HAZARDS MODELS; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES; TIME FACTORS;

EID: 77957700640     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.026     Document Type: Article

References (40)

1. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
2. Yeghiazarians Y., Braunstein J.B., Askari A., Stone P.H. Unstable angina pectoris. N Engl J Med 2000, 342:101-114.
3. Antmann E.M., Cohen M., Bernink P.J.L.M., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000, 284:835-842.
4. Mulvihill N.T., Foley J.B. Inflammation in acute coronary syndromes. Heart 2002, 87:201-204.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Danesh J., Wheeler J.G., Hirschfield G.M., et al. V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
7. Lindalh B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000, 343:1139-1147.
8. Blankenberg S., Mc Queen M.J., Smieja M., et al. Comparative impact of multiple biomarkers and N-terminal pro brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2006, 114:201-208.
9. De Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
10. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L. Cystatin C-a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004, 110:2342-2348.
11. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000, 36:970-1062.
12. Bertrand M.E., Simoons M.L., Fox K.A., et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002, 23:1809-1840.
13. Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001, 38:2114-2130.
14. Terkelsen C.J., Lassen J.F., Norgaard B.L., et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J 2005, 26:18-26.
15. Hasdai D., Behar S., Wallentin L., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002, 23:1190-1201.
16. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002, 105:1412-1415.
17. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11 A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31:1460-1465.
18. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999, 100:1958-1963.
19. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
20. Ridker P.M., Cannon C.P., Morrow D., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators, C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
21. Blankenberg S., Yusuf S. The inflammatory hypothesis. Any progress in risk stratification and therapeutic targets?. Circulation 2006, 114:1557-1560.
22. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997, 96:1102-1108.
23. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
24. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006, 166:1368-1373.
25. Tateishi J., Masutani M., Ohyanagi M., Iwasaki T. Transient increase in plasma brain (B-Type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000, 23:776-780.
26. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H. White HD for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004, 110:3206-3212.
27. Bazzino O., Fuselli J.J., Botto F., et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2004, 25:859-866.
28. Steen H., Futterer S., Merten C., Jünger C., Katus H.A., Giannitsis E. Relative role of Nt-pro BNP and cardiac troponin T at 96hours for estimation of infarction size and left ventricular function after acute myocardial infarction. J Cardiovasc Magn Reson 2007, 9:749-758.
29. Vanzetto G., Jacon P., Calizzano A., et al. N-terminal pro-brain natriuretic peptide predicts myocardial ischemia and is related to postischemic left ventricular dysfunction in patients with stable coronary artery disease. J Nucl Cardiol 2007, 14:83642.
30. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997, 96:4204-4210.
31. Arnau Vives M.A., Rueda Soriano J., Martinez Dolz L.V., et al. Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-Q-wave myocardial infarction. Rev Esp Cardiol 2002, 55:622-630.
32. Eggers K.M., Lagerqvist B., Vengue P., Wallentin L., Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2009, 54:365-367.
33. Shemesh T., Rowley K.G., Jenkins A.J., Best J.D., O'Dea K. C-reactive protein concentrations are very high and more stable over time than the traditional vascular risk factors total cholesterol and systolic blood pressure in an Australian Aboriginal Cohort. Clin Chem 2009, 55:336-341.
34. Aziz N., Fahey J.L., Detels R., Butch A.W. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diag Lab Immunol 2003, 10:652-657.
35. Ledue T.B., Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003, 49:1258-1271.
36. Cauliez B., Guignery J., Marinier S., Mariau I., Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 2008, 45:318-319.
37. Kenis G., Teunissen C., De Jongh R., Bosmans E., Steinbusch H., Maes M. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine 2002, 19:228-235.
38. Aziz N., Nishanian P., Mitsuyasu R., Detels R., Fahey J.L. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999, 6:89-95.
39. Tworoger S.S., Hankinson S.E. Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 2006, 17:889-899.
40. Tworoger S.S., Hankinson S.E. Collection, processing and storage of biological samples in epidemiological studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 2006, 15:1578-1581.